

Stanford



Sumit Shah

Clinical Assistant Professor, Medicine - Oncology

CLINICAL OFFICES

- **Stanford Cancer Center**

875 Blake Wilbur Dr Clinic E

Stanford, CA 94305

Tel (650) 498-6000

Fax (650) 736-7379

Bio

BIO

Dr. Sumit Shah specializes in the management of advanced urologic malignancies such as prostate, kidney, bladder, and testicular cancers. He also serves as an investigator on numerous clinical trials, with a focus on novel immunotherapy agents. His academic interests also include digital health technologies and novel healthcare delivery services, both in the domestic and international setting. Dr. Shah graduated with distinction in biomedical engineering from Duke University, received his medical doctorate from Stanford University, and Masters in Public Health from Harvard University. He completed his internal medicine residency at the University of California, San Francisco (UCSF) where he stayed on faculty for one year before returning to Stanford for his fellowship training in medical oncology, where he now serves on the faculty.

CLINICAL FOCUS

- Oncology
- Prostate Cancer
- Kidney Cancer
- Bladder Cancer
- Testicular Cancer/Germ Cell Tumor
- Immunotherapy

ACADEMIC APPOINTMENTS

- Clinical Assistant Professor, Medicine - Oncology
- Member, Stanford Cancer Institute

HONORS AND AWARDS

- US Fulbright Scholar, South Korea (2005)

PROFESSIONAL EDUCATION

- Fellowship: Stanford University Hematology and Oncology Fellowship (2017) CA
- Medical Education: Stanford University School of Medicine (2010) CA

- Board Certification: Oncology, American Board of Internal Medicine (2017)
- Board Certification: Internal Medicine, American Board of Internal Medicine (2013)
- Residency: UCSF Internal Medicine Residency (2013) CA
- Fellowship, Stanford University Hospital , Oncology/Hematology (2017)
- Residency, University of California, San Francisco (UCSF) , Internal Medicine (2013)
- MPH, Harvard School of Public Health (2010)
- MD, Stanford School of Medicine (2010)
- BSE, Duke University (2004)

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CLINICAL TRIALS

- Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC), Recruiting

Teaching

STANFORD ADVISEES

Academic Advising Dean

David Altman, Ankit Baghel, Ellie Beam, Preksha Bhagchandani, Hriday Bhambhvani, Christian Calderon, Tim Chai, Samuel Cohen, Shayna Cooperman, Kimberly DeBruler, Alexis Doyle, Areian Eghbali, Sofia Essayan-Perez, Mollie Friedlander, Cesar Garcia, Luis Garcia, Jason Gomez, Cayo Gonzalez, Jonathan Goodman, Margaret Guo, Jessica Hampton, Shammah Ike, Candice Kim, Kathy Ku, Daniel Liu, Sofia Luna, Lucy Ma, Payton Marshall, Aviva Mattingly, Jack Michaud, Paras Minhas, Daniel Mokhtari, Yanick Mulumba, Sidney Owen, Ragini Phansalkar, Santiago Sanchez, Ben Schwartz, Vinita Shivakumar, Benjie Smith, Jodi So, Austin Valido, Kunal Varshneya, Harsh Wadhwa, Allan Wang, Songnan Wang, Christine Xu, Christine Yeh, Willemijn van Deursen

Publications

PUBLICATIONS

- **Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.** *Lancet (London, England)*
Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y. n., Rubinstein, S. M., Rivera, D. R., Shete, S. n., Hsu, C. Y., Desai, A. n., de Lima Lopes, G. n., Grivas, P. n., Painter, C. A., Peters, et al
2020
- **First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A. D., O'Rourke, T., Narayanan, S., Papadopoulos, K., Fisher, G. A., Villalobos, V., Prohaska, et al
2019: JCO1802018
- **Consolidative Radiotherapy in Metastatic Urothelial Cancer.** *Clinical genitourinary cancer*
Shah, S., Zhang, C. A., Hancock, S., Fan, A., Skinner, E., Srinivas, S.
2017
- **Reply to R. Kebudi et al.** *JCO oncology practice*
Tsu-Yu Wu, J., Kwon, D. H., Glover, M., Henry, S., Wood, D., Rubin, D., Koshkin, V., Schapira, L., Shah, S. A.
2021: OP2100105

- **PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
Baratto, L., Song, H., Duan, H., Hatami, N., Bagshaw, H., Buyyounouski, M., Hancock, S., Shah, S. A., Srinivas, S., Swift, P., Moradi, F., Davidzon, G. A., Iagaru, et al
2021
- **Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors.** *JACC. CardioOncology*
Waliany, S., Neal, J. W., Reddy, S., Wakelee, H., Shah, S. A., Srinivas, S., Padda, S. K., Fan, A. C., Colevas, A. D., Wu, S. M., Witteles, R. M., Zhu, H.
2021; 3 (1): 137–39
- **Racial and socioeconomic disparities in retroperitoneal lymph node dissection and survival in nonseminomatous germ cell tumor: A population-based study.** *Urologic oncology*
Bhambhani, H. P., Greenberg, D. R., Kasman, A. M., DeRouen, M. C., Cheng, I., Eisenberg, M. L., Shah, S. A.
2021
- **Remote Oncology Care: Review of Current Technology and Future Directions** *CUREUS*
McGregor, B. A., Vidal, G. A., Shah, S. A., Mitchell, J. D., Hendifar, A. E.
2020; 12 (8)
- **Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study.** *Cancer discovery*
Rivera, D. R., Peters, S., Panagiotou, O. A., Shah, D. P., Kuderer, N. M., Hsu, C., Rubinstein, S. M., Lee, B. J., Choueiri, T. K., de Lima Lopes, G., Grivas, P., Painter, C. A., Rini, et al
2020
- **Development of robust artificial neural networks for prediction of 5-year survival in bladder cancer.** *Urologic oncology*
Bhambhani, H. P., Zamora, A., Shkolyar, E., Prado, K., Greenberg, D. R., Kasman, A. M., Liao, J., Shah, S., Srinivas, S., Skinner, E. C., Shah, J. B.
2020
- **Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19)**
Rubinstein, S., Grivas, P., Choueiri, T. K., Kuderer, N., Shah, D., Rivera, D. R., Gupta, S., Bilen, M., Halfdanarson, T., Doroshov, D., Wehbe, F., Shah, S., Shyr, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Association of renal cell carcinoma subtypes with race/ethnicity and comorbid medical conditions**
Lichtensztajn, D. Y., Hofer, B. M., Leppert, J. T., Brooks, J. D., Chung, B., Shah, S. A., DeRouen, M. C., Gomez, S. L., Cheng, I.
AMER ASSOC CANCER RESEARCH.2020
- **Testicular cancer in Hispanics: Incidence of subtypes over time according to neighborhood sociodemographic factors in California**
DeRouen, M. C., McKinley, M., Shah, S. A., Borno, H. T., Aoki, R., Lichtensztajn, D. Y., Leppert, J. T., Brooks, J. D., Chung, B., Gomez, S. L., Cheng, I.
AMER ASSOC CANCER RESEARCH.2020
- **Testicular cancer in Hispanics: incidence of subtypes over time according to neighborhood sociodemographic factors in California.** *Cancer causes & control : CCC*
DeRouen, M. C., McKinley, M., Shah, S. A., Borno, H. T., Aoki, R., Lichtensztajn, D. Y., Leppert, J. T., Brooks, J. D., Chung, B. I., Gomez, S. L., Cheng, I.
2020
- **DEVELOPING THE ADVANCED PRACTICE ROLE IN INFUSION TREATMENT AREA**
Shah, D., Kuriakose, C., Healy, D., Shah, S.
ONCOLOGY NURSING SOC.2020
- **Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study.** *Journal for immunotherapy of cancer*
Martinez Chanza, N., Xie, W., Issa, M., Dzimitrowicz, H., Tripathi, A., Beuselink, B., Lam, E., Zakharia, Y., Mckay, R., Shah, S., Mortazavi, A., R Harrison, M., Sideris, et al
2020; 8 (1)
- **Remote Oncology Care: Review of Current Technology and Future Directions.** *Cureus*
McGregor, B. A., Vidal, G. A., Shah, S. A., Mitchell, J. D., Hendifar, A. E.
2020; 12 (8): e10156

- **Changes in Cancer Management due to COVID-19 Illness in Patients with Cancer in Northern California.** *JCO oncology practice*
Wu, J. T., Kwon, D. H., Glover, M. J., Henry, S. n., Wood, D. n., Rubin, D. L., Koshkin, V. S., Schapira, L. n., Shah, S. A.
2020: OP2000790
- **Feasibility and design of a cloud-based digital platform in patients with advanced cancer.**
Roy, M., Hall, E., Velazquez, B., Shah, S., Fardeen, T., Cunanan, K., San Pedro-Salcedo, M., Wakelee, H. A., Neal, J. W., Padda, S., Das, M., Fan, A. C., Srinivas, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **Retrospective analysis of the safety and efficacy of immune checkpoint inhibitors (CPI) among patients (pts) with pre-existing autoimmune disorders (AD) and renal cell carcinoma (RCC) or urothelial carcinoma (UC).**
Chanza, N., Xie, W., Issa, M., Dzimitrowicz, H., Tripathi, A., Beuselinck, B., Lam, E., Zakharia, Y., Mckay, R. R., Shah, S., Mortazavi, A., Harrison, M., Choueiri, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study** *LANCET ONCOLOGY*
Changa, N., Xie, W., Bilen, M., Dzimitrowicz, H., Burkart, J., Geynisman, D. M., Balakrishnan, A., Bowman, I., Jain, R., Stadler, W., Zakharia, Y., Narayan, V., Beuselinck, et al
2019; 20 (4): 581–90
- **Undertreatment of High-Risk Localized Prostate Cancer in the California Latino Population.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Lichtensztajn, D. Y., Leppert, J. T., Brooks, J. D., Shah, S. A., Sieh, W., Chung, B. I., Gomez, S. L., Cheng, I.
2018; 16 (11): 1353–60
- **Prognostic factors for pancreatic metastases in renal cell cancer.**
Chung, A., Li, S., Shah, S., Fan, A. C., Srinivas, S.
AMER SOC CLINICAL ONCOLOGY.2016
- **In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study** *BLOOD*
Kim, Y. H., Gratzinger, D., Harrison, C., Brody, J. D., Czerwinski, D. K., Ai, W. Z., Morales, A., Abdulla, F., Xing, L., Navi, D., Tibshirani, R. J., Advani, R. H., Lingala, et al
2012; 119 (2): 355-363